|
CBRE, world’s leading real estate consulting firm, released its report, ‘Global Life Sciences Atlas,’ profiling some of the world’s most important life sciences hubs—traditional and emerging- and examining investment and construction trends impacting the life sciences industry. The growing prominence of the life sciences industry has significantly impacted the growth of real estate development globally, with more than 35 million sq. ft. of lab/research and development (R&D) properties under construction last year.
While US markets top the world’s largest life sciences R&D centres, other mainstays can be found in Asia-Pacific (Hyderabad, Beijing, Shanghai, Greater Tokyo), Canada (Toronto, Montreal) and Europe (Cambridge, UK, Paris). As per the findings, Hyderabad emerged as a prominent global centre of life sciences manufacturing activity in India.
The report points out that Hyderabad is the key contributor and largest life sciences manufacturing and R&D cluster, undertaking research, training, and manufacturing. The city accounts for nearly one-third of the country’s pharmaceutical production, one-fifth of its pharmaceutical exports, and one-third of global vaccine output. Gross office leasing space by life sciences firms in India increased by 56% YoY to about 5.8 million sq. ft., witnessing the highest-ever leasing activity by the sector. This growth has been driven by several factors, including increased foreign direct investment (FDI), enhanced manufacturing capabilities, a cost-effective talent pool, greater emphasis on R&D, and demographic trends such as a rising population and increasing life expectancy.
Hyderabad’s life sciences industry landscape has the Genome Valley is home to over 200 biotech and pharmaceutical companies from 18 countries. Six of the world’s top 10 research and development (R&D) companies have facilities in Genome Valley. Over 20 life sciences and medical technology incubators are in Hyderabad which is the highest concentration in India. Leading players include Aurigene Pharma Services, Bharat Biotech, Biological E, Chemo, Cohance, Ferring, Indian Immunologicals, Novartis, Sai Life Sciences and Syngene. This momentum according to the report is being further reinforced by the Government of Telangana. The recently launched Life Sciences Policy 2023–2028 offers a range of fiscal incentives and ready-to-use infrastructure to attract investment.
Anshuman Magazine, chairman & CEO - India, South-East Asia, Middle East & Africa, CBRE, said, “Hyderabad’s rise as a global life sciences manufacturing hub reflects the growing maturity and competitiveness of India’s life sciences sector. The city’s robust infrastructure, progressive policies, and exceptional scientific talent have made it a preferred destination for global pharmaceutical and biotech firms. As India’s life sciences industry gains unprecedented momentum, Hyderabad is at the heart of this transformation-its integrated clusters and visionary frameworks positioning Genome Valley among the world’s most dynamic life sciences hubs and signalling India’s readiness to lead the next phase of global life sciences growth.”
Ada Choi, head of research -APAC, CBRE, said, “The increasing prominence of the life sciences industry is driving substantial real estate development on a global scale. The Asia-Pacific region is at the forefront of this trend, leading global life sciences construction activity. Notably, China currently exhibits the highest volume of ongoing laboratory construction worldwide, while India is establishing itself as a compelling hub for life sciences manufacturing. This underscores the robust growth trajectory of the life sciences sector in the region and suggests that strengthening demand dynamics will likely fuel further expansion in the coming years.”
|